Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

The research could further complicate the polarized politics of abortion because the drug in the study is the key ingredient in a pill used for emergency contraception.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

Atrial fibrillation, or A-fib , is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even premature death.Author ...

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price ...

NYSE:BSX) Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation ...

Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves ...

The researchers found that the ePRO group had significant improvements in mean PSQ score and QOI score regarding treatment ...